脱镁叶绿酸盐 A结构式
|
常用名 | 脱镁叶绿酸盐 A | 英文名 | Pheophorbide A |
---|---|---|---|---|
CAS号 | 15664-29-6 | 分子量 | 592.68 | |
密度 | 1.3±0.1 g/cm3 | 沸点 | 1019.0±65.0 °C at 760 mmHg | |
分子式 | C35H36N4O5 | 熔点 | 191-195°C (lit.) | |
MSDS | 中文版 美版 | 闪点 | 570.1±34.3 °C |
脱镁叶绿酸盐 A用途菲叶绿酸A是叶绿素降解途径中的一种中间产物,可作为光敏剂使用。菲叶绿苷A是一种具有抗肿瘤活性的淋巴血管激活剂[1]。 |
中文名 | 脱镁叶绿酸盐 A |
---|---|
英文名 | pheophorbide a |
中文别名 | 脱镁叶绿酸-A |
英文别名 | 更多 |
密度 | 1.3±0.1 g/cm3 |
---|---|
沸点 | 1019.0±65.0 °C at 760 mmHg |
熔点 | 191-195°C (lit.) |
分子式 | C35H36N4O5 |
分子量 | 592.68 |
闪点 | 570.1±34.3 °C |
精确质量 | 592.268555 |
PSA | 136.97000 |
LogP | 6.76 |
外观性状 | 蓝色至暗棕色粉末 |
蒸汽压 | 0.0±0.3 mmHg at 25°C |
折射率 | 1.630 |
储存条件 | 20°C,惰性气体,避光 |
分子结构 | 五、分子性质数据: 1、 摩尔折射率:164.45 2、 摩尔体积(m3/mol):462.1 3、 等张比容(90.2K):1275.2 4、 表面张力(dyne/cm):57.9 5、 极化率(10-24cm3):65.19 |
计算化学 | 1.疏水参数计算参考值(XlogP):5.2 2.氢键供体数量:3 3.氢键受体数量:7 4.可旋转化学键数量:7 5.互变异构体数量:1001 6.拓扑分子极性表面积138 7.重原子数量:44 8.表面电荷:0 9.复杂度:1130 10.同位素原子数量:0 11.确定原子立构中心数量:3 12.不确定原子立构中心数量:0 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:1 |
更多 | 1.性状:未确定 2.密度(g/mL,25/4℃):未确定 3.相对蒸汽密度(g/mL,空气=1):未确定 4.熔点(ºC):未确定 5.沸点(ºC,常压):未确定 6.沸点(ºC,5.2kPa):未确定 7.折射率:未确定 8.闪点(ºC):未确定 9.比旋光度(º):未确定 10.自燃点或引燃温度(ºC):未确定 11.蒸气压(kPa,25ºC):未确定 12.饱和蒸气压(kPa,60ºC):未确定 13.燃烧热(KJ/mol):未确定 14.临界温度(ºC):未确定 15.临界压力(KPa):未确定 16.油水(辛醇/水)分配系数的对数值:未确定 17.爆炸上限(%,V/V):未确定 18.爆炸下限(%,V/V):未确定 19.溶解性:未确定 |
危害码 (欧洲) | Xn |
---|---|
危险品运输编码 | NONH for all modes of transport |
Antioxidant-photosensitizer dual-loaded polymeric micelles with controllable production of reactive oxygen species.
Int. J. Pharm. 471(1-2) , 339-48, (2014) Poly(ethylene glycol)-b-poly(caprolactone) (PEG-b-PCL) micelles dually loaded with both pheophorbide a (PhA) as a photosensitizer and β-carotene (CAR) as a singlet oxygen ((1)O2) scavenger were design... |
|
In-vitro evidence of enhanced breast cancer resistance protein-mediated intestinal urate secretion by uremic toxins in Caco-2 cells.
J. Pharm. Pharmacol. 67(2) , 170-7, (2015) It has been reported that intestinal urate excretion is increased at chronic kidney disease (CKD) state. In this report, whether uremic toxins are involved in the upregulation of intestinal breast can... |
|
ABCG2 transporter inhibitor restores the sensitivity of triple negative breast cancer cells to aminolevulinic acid-mediated photodynamic therapy.
Sci. Rep. 5 , 13298, (2015) Photosensitizer protoporphyrin IX (PpIX) fluorescence, intracellular localization and cell response to photodynamic therapy (PDT) were analyzed in MCF10A normal breast epithelial cells and a panel of ... |
Inchi=1/C35H36N4o5/C1-8-19-15(3)22-12-24-17(5)21(10-11-28(40)41)32(38-24)30-31(35(43)44-7)34(42)29-18(6)25(39-33(29)30)14-27-20(9-2)16(4)23(37-27)13-26(19)36-22/H8,12-14,17,21,31,36,39H,1,9-11H2,2-7H3,(H,40,41)/B22-12-,23-13-,24-12-,25-14-,26-13-,27-14 |
3-[(3S,4S,21R)-9-ethenyl-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxophorbin-3-yl]propanoic acid |
EINECS 239-738-5 |
[3s-(3alpha,4beta,21beta)]-ramethyl-20-oxo |
3-phorbinepropanoicacid,9-ethenyl-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tet |
13-Epi-phaeophorbide-a |
Rel-3-[(3R,4R)-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-9-vinylphorbin-3-yl]propanoic acid |
3-[(3S,4S,21R)-14-Ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-9-vinylphorbin-3-yl]propanoic acid |
3-Phorbinepropanoic acid,9-ethenyl-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-,(3S,4S) |
[3S-(3alpha,4beta,21beta)]-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-9-vinylphorbine-3-propionic acid |
(3S,4S)-9-Ethenyl-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid |
Pheophorbide A |
(3S-(3a,4b,21b))-14-Ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-9-vinylphorbine-3-propionic Acid |
3-[(3S,4S,21R)-14-Ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-9-vinyl-3-phorbinyl]propanoic acid |
3-Phorbinepropanoic acid, 9-ethenyl-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-, (3S,4S,21R)- |
Demagnesia chloric acid -a |